Author index

Abeler, V.M. *see* Kaern, J.
Adams, D.J. *see* Patel, K.R.
Adcock, L.L. *see* Carter, J.R.
Akazawa, K. *see* Kamura, T.
Al-Nafussi, A.I., Colquhoun, M.K. & Williams, A.R.W. Accuracy of cervical smears in predicting the grades of cervical intraepithelial neoplasia, 89
Al-Nafussi, A.I., Klys, H.S., Rebello, G., Kelly, C., Kerr, G. & Cowie, V. The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in the uterine cervix and cervical squamous neoplasia, 154
Aleksic, M. *see* Kesic, V.I.
Ali, S.W. *see* Patel, K.R.
Andersen, E. *see* Bertelsen, K.
Andersen, E.S., Husth, M., Joergensen, A. & Nielsen, K. Laser conization for microinvasive carcinoma of the cervix. Short-term results, 183
Andersen, J.E. *see* Bertelsen, K.
Arrand, J.R. *see* Connor, M.E.
Astley, S. *see* Patel, K.R.

Baekelandt, M., Kockx, M., Wesling, F. & Gerris, J. Primary adenocarcinoma of the fallopian tube. Review of the literature, 65
Baoicchi, G. *see* Scambia, G.
Barton, D.P.J., Hoffman, M.S., Roberts, W.S., Fiorica, J.V., Finan, M.A., Gleeson, N. & Cavanagh, D. Use of local flaps in the preservation of fecal continence following resection of perianal neoplasias, 318
Battaglia, F. *see* Scambia, G.
Ben-Baruch, G. *see* Menczer, J.
Benedetti Panici, P. *see* Scambia, G.
Bertelsen, K., Hølund, B. & Andersen, E. Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancer, 72
Bertelsen, K., Hølund, B., Andersen, J.E., Nielsen, K., Strøyer, L. & Ladehoff, P. Prognostic factors and adjuvant treatment in early epithelial ovarian cancer, 211
Buerskens, M.L. *see* Rose, P.G.
Benyon, D.W.G., Lopes, A., Daras, B. & Monaghan, J.M. Radical vulvectomy and groin node dissection in a patient with chronic neutropenial–maintenance of leucocyte colony stimulating factor, 405
Black, B. *see* Thomas, G.M.
Boltz, E.M. *see* Leary, J.A.
Bormer, O.P. *see* Makar, A. Ph.
Bouma, J. & Dankert, J. Infection after radical abdominal hysterectomy and pelvic lymphadenectomy: prevention of infection with a two-dose peri-operative antibiotic prophylaxis, 94
Brenner, H. *see* Menczer, J.
Bridges, J.E., Yeung, Y., Hammond, I.G. & McCartney, A.J. En bloc resection of epithelial ovarian tumors with concomitant rectosigmoid colectomy: the KEHM experience, 199
Brown, M.B. *see* Nahhas, W.A.
Buckley, C.H. *see* Guo, Li-Na
Buckley, C.H. *see* Sivridis, E.
Burger, M.P.M. & Hollema, H. The reliability of the histologic diagnosis in colposcopically directed biopsies. A plea for LETZ, 385
Buxton, E.J. *see* Finn, C.B.
Buxton, E.J. *see* Shafi, M.I.

Carl, J. & Tropé, C. Gestational trophoblastic tumors: cytostatic treatment response evaluated from hCG modelling, 265
Carlson, J.W. *see* Carter, J.R.
Carson, L.F. *see* Carter, J.R.
Carter, J.R., Fowler, J.M., Carlson, J.W., Carson, L.F., Adcock, L.L. & Twiggs, L.B. Prediction of malignancy using transvaginal color flow Doppler in patients with gynecologic tumors, 279
Cavanagh, D. *see* Barton, D.P.J.
Chamorro, T. *see* Karlan, B.Y.
Chawner, L. *see* Guo, Li-Na
Clark, M.A. *see* Nahhas, W.A.
Colquhoun, M.K. *see* Al-Nafussi, A.I.
Connor, M.E., Davidson, S.E., Stern, P.L., Arrand, J.R. & West, C.M.L. Evaluation of multiple biologic parameters in cervical carcinoma: high macrophage infiltration in HPV-associated tumors, 103
Coronetta, F. *see* Scambia, G.
Cowie, V. *see* Al-Nafussi, A.I.
Creaseman, W.T. *see* Eddy, G.L.
Cruikshank, D. *see* Fayers, P.M.

Dankert, J. *see* Bouma, J.
Daras, B. *see* Beynon, D.W.G.
Davidson, S.E. *see* Connor, M.E.
Davis, J.A. *see* Nwabineli, N.J.
De Palo, G. *see* Mangioni, C.
Del Vecchio, M. *see* Mangioni, C.
Dembo, A.J. *see* Thomas, G.M.
Di Stefano, P. *see* Scambia, G.
Doris, C.P. *see* Leary, J.A.
Dunn, J. *see* Finn, C.B.
Dunn, J.A. *see* Shafi, M.I.

Eddy, G.L., Jenrette III, J.M. & Creaseman, W.T. Effect of radiotherapeutic technique on local control in primary vaginal carcinoma, 399
Eifel, P. *see* Patton, T.J.

Fayers, P.M., Rustin, G., Wood, R., Nelstrop, A., Leonard, R.C.F., Wilkinson, P., Cruikshank, D., McAllister, E.J., Redman, C.W.E., Parker, D., Scott, I.V., Slevin, M.L. & Roulston, J.E. The prognostic value of serum CA125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working

Party in Gynaecological Cancer, 285
Ferrandini, G. *see* Scambia, G.
Finan, M.A. *see* Barton, D.P.J.
Finan, M.A. *see* Hachisuga, T.
Finan, M.A., Roberts, W.S. & Kavanagh, J.J. Ovarian Sertoli-Leydig cell tumor: success with salvage therapy, 189
Finn, C.B. *see* Shafi, M.I.
Finn, C.B., Dunn, J., Buxton, E.J., Luesley, D.M. & Shafi, M. Can we predict a high risk group in stage I epithelial ovarian cancer? 226
Fiorica, J.V. *see* Barton, D.P.J.
Follen Mitchell, M. *see* Patton, T.J.
Fowler, J.M. *see* Carter, J.R.
Fowler, J.M. *see* Karlan, B.Y.
Fox, H. *see* Guo, Li-Na
Fox, H. *see* Sivridis, E.
Frank, T.S. *see* Helm, C.W.
Friedlander, M.L. *see* Leary, J.A.
Fu, W.Y., Heale, E. & Shun, F.W.W. Serum lipid-associated sialic acid levels in gynecologic malignancies, 143
Fujita, M., Inque, M., Tanizawa, O., Minagawa, J., Tamada, T. & Tani, T. Retrospective review of 41 patients with endodermal sinus tumor of the ovary, 329
Fukuda, K. *see* Hachisuga, T.
Furui, T. *see* Imai, A.

Gastorf, L. *see* Patton, T.J.
Gerris, J. *see* Baekelandt, M.
Gleeson, N. *see* Barton, D.P.J.
Gore, H. *see* Helm, C.W.
Greenberg, S. *see* Karlan, B.Y.
Guo, Li-Na, Wilkinson, N., Buckley, C.H., Fox, H., Hale, R.J. & Chawner, L. Proliferating cell nuclear antigen (PCNA) immunoreactivity in ovarian serous and mucinous neoplasms: diagnostic and prognostic value, 391

Hachisuga, T., Fukuda, K., Uchiyama, M., Matsuo, N., Iwasaka, T. & Finan, M.A., Ultraradical surgery for advanced carcinoma of the vulva: an update, 369
Hacker, N.F. *see* Proietto, A.
Hale, R.J. *see* Guo, Li-Na
Hammond, I.G. *see* Bridges, J.E.
Hatch, K.D. *see* Potter, M.E.
Heale, E. *see* Fu, W.Y.
Helm, C.W., Kinney, W.K., Keeney, G., Lawrences, W.D., Frank, T.S., Gore, H., Reynolds, R.K., Soong, S.-J., Partridge, E.E., Roberts, J., Podrate, K. & Shingleton, H.M. A matched study of surgically treated stage IB adenosquamous carcinoma and adenocarcinoma of the uterine cervix, 245
Hitchcock, A., Johnson, J., McDowell, K. & Johnson, I.R. A retrospective study into the occurrence of cervical glandular atypia in cone biopsy specimens from 1977–1978 with clinical follow-up, 164
Hoffman, M.S. *see* Barton, D.P.J.
Hollema, H. *see* Burger, M.P.M.
Hølund, B. *see* Bertelsen, K.
Houghton, C.R.S. *see* Leary, J.A.
Hunter, R.E. *see* Rose, P.G.
Husth, M. *see* Andersen, E.S.

Iacobelli, S. *see* Scambia, G.
Imachi, M. *see* Karu, T.
Imai, A., Ohno, T., Furui, T., Takahashi, K., Matsuda, T. & Tamaya, T. Gonadotropin interstitial radiotherapy and infusional chemotherapy for recurrent gynecologic malignancies, 304
Inque, M. *see* Fujita, M.
Ito, Kiyoshi, Sasano, Hironobu, Watanabe, Keiko, Ozawa, Nobuyoshi, Sato, Shinji & Yajima, Akira. Immunohistochemical study of PCNA (proliferating cell nuclear antigen) in normal and abnormal endometrium, 122
Iwasaka, T. *see* Hachisuga, T.

Jayalakshmi, P. *see* Sivanesarathnam, V.
Jenrette III, J.M. *see* Eddy, G.L.
Joergensen, A. *see* Andersen, E.S.
Johnson, I.R. *see* Hitchcock, A.
Johnson, J. *see* Hitchcock, A.
Jones, L.M.H. *see* Longfield, J.C.
Jordan, J.A. *see* Shafi, M.I.

Kaern, J. *see* Makar, A. Ph.
Kaern, J., Tropé, C.G., Kristensen, G.B., Abeler, V.M. & Petterson, E.O. DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary, 349
Kaku, T. *see* Kamura, T.
Kamura, T., Tsukamoto, N., Tsuruchi, N., Kaku, T., Saito, T., To, N., Akazawa, K. & Nakano, H. Histopathological prognosis factors in stage IIb cervical carcinoma treated with radical hysterectomy and pelvic node dissection—an analysis with mathematical statistics, 219
Kanura, T. *see* Karu, T.
Karlan, B.Y., Chamorro, T., Fowler, J.M., Muderspach, L.I., Greenberg, S. & Lagasse, L.D. Concurrent interstitial radiotherapy and infusional chemotherapy for recurrent gynecologic malignancies, 304
Karu, T., Matsuo, K., Tsukamoto, N., Shimmoto, T., Sugihara, K., Tsuruchi, N., To, N., Kanura, T., Saito, T., Imachi, M. & Nakano, H. Endometrial carcinoma in women aged 40 years or younger: a Japanese experience, 147
Kavanagh, J.J. *see* Finan, M.A.
Keeney, G. *see* Helm, C.W.
Kefford, R.F. *see* Leary, J.A.
Kehoe, S. *see* Shafi, M.I.
Kelly, C. *see* Al-Nafussi, A.I.
Kerr, G. *see* Al-Nafussi, A.I.
Kesic, V.I., Soutter, W.P., Sulovic, V., Juznic, N., Aleksic, M. & Ljubic, A. A comparison of cytology and cervicography in cervical screening, 395
Kim, R.Y. Radiotherapeutic management in carcinoma of the uterine cervix: current status, 337
Kinney, W.K. *see* Helm, C.W.
Kjørstad, K.E. *see* Nordal, E.N.
Klys, H.S. *see* Al-Nafussi, A.I.
Kockx, M. *see* Baekelandt, M.

Kristensen, G.B. *see* Kaern, J.
Kristensen, G.B. *see* Makar, A. Ph.

Lacey, C.J.N. *see* Patel, K.R.
Ladehoff, P. *see* Bertelsen, K.
Lagasse, L.D. *see* Karlan, B.Y.
Lawrences, W.D. *see* Helm, C.W.
Leary, J.A., Doris, C.P., Boltz, E.M., Houghton, C.R.S., Kefford, R.F. & Friedlander, M.L. Investigation of loss of heterozygosity at specific loci on chromosomes 3p, 6q, 11p, 17p and 17q in ovarian cancer, 293
Leonard, R.C.F. *see* Fayers, P.M.
Ljubic, A. *see* Kesic, V.I.
Longfield, J.C., Jones, L.M.H., Thompson, S., Monaghan, J.M. & Turner, G.A. Increased levels of a lower molecular weight form of secretory component in cervical scrapes from women with cervical intraepithelial neoplasia, 253
Lopes, A. *see* Beynon, D.W.G.
Luesley, D.M. *see* Finn, C.B.
Luesley, D.M. *see* Shafi, M.I.

McAllister, E.J. *see* Fayers, P.M.
McCartney, A.J. *see* Bridges, J.E.
McDowell, K. *see* Hitchcock, A.
Makar, A. Ph., Kaern, J., Kristensen, G.B., Vergote, I., Børmer, O.P. & Tropé, C.G. Evaluation of serum CA125 level as a tumor marker in borderline tumors of the ovary, 299
Makar, A.Ph., Kristensen, G.B., Nesland, J., Børmer, O.P. & Tropé, C.C. Serum CA 125 as a tumor marker and the expression of c-erbB-2 oncogene in tubal malignancies, 116
Mancuso, S. *see* Scambia, G.
Mangioni, C., De Palo, G., Marubini, E. & Del Vecchio, M. Surgical pathologic staging in apparent stage I endometrial carcinoma, 373
Marubini, E. *see* Mangioni, C.
Matsuda, T. *see* Imai, A.
Matsuo, K. *see* Karu, T.
Matsuo, N. *see* Hachisuga, T.
Menczer, J., Ben-Baruch, G., Rizel, S. & Brenner, H. Extraperitoneal chemotherapy of ovarian cancer patients with a negative second-look laparatomy, 359
Miller, D. *see* Patton, T.J.
Minagawa, J. *see* Fujita, M.
Monaghan, J.M. *see* Beynon, D.W.G.
Monaghan, J.M. *see* Longfield, J.C.
Muderspach, L.I. *see* Karlan, B.Y.
Myhr, T. *see* Thomas, G.M.

Nahhas, W.A., Clark, M.A. & Brown, M.B. 'Abnormal' Papanicoulaou smears and colposcopy in pregnancy: ante- and post-partum findings, 239
Nakano, H. *see* Kamura, T.
Nakano, H. *see* Karu, T.
Natali, P. *see* Scambia, G.
Neely Atkinson, E. *see* Patton, T.J.
Neilsen, K. *see* Bertelsen, K.
Nelstrop, A. *see* Fayers, P.M.
Nesland, J. *see* Makar, A.PH.
Nielsen, K. *see* Andersen, E.S.
Nordal, R.N., Kjørstad, K.E., Stenwig, A.E. & Tropé, C.C. Leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) of the uterus. A survey of patients treated in the Norwegian Radium Hospital, 1976–1985, 110
Nwabineli, N.J., Walsh, D.J. & Davis, J.A. Urinary drainage following radical hysterectomy for cervical carcinoma—a pilot comparison of urethral and suprapubic routes, 208

Ohno, T. *see* Imai, A.
Ong, G. *see* Sivanesarathnam, V.
O'Reilley, S.M. & Rustin, G.J.S. Mismanagement of choriocarcinoma due to a false low HCG measurement, 189
Ozawa, Nobuyoshi *see* Ito, Kiyoshi

Parker, D. *see* Fayers, P.M.
Partridge, E.E. *see* Helm, C.W.
Patel, K.R., Astley, S., Adams, D.J., Lacey, C.J.N., Ali, S.W. & Wells, M. Expression of cytochrome P450 enzymes in the cervix. An immunohistochemical study, 159
Patton, T.J., Follen Mitchell, M., Neely Atkinson, E., Eifel, P., Gastorf, L., Yancey, C., Miller, D. & Wharton, J.T. Parameters of small bowel dysfunction in cervical cancer patients undergoing radiotherapy, 175
Petterson, E.O. *see* Kaern, J.
Piantelli, M. *see* Scambia, G.
Podrate, K. *see* Helm, C.W.
Potter, M.E., Spencer, S., Soong, S.-J. & Hatch, K.D. The influence of staging laparotomy for cervical cancer on patterns of recurrence and survival, 169
Pringle, J.F. *see* Thomas, G.M.
Prioetto, A. & Hacker, N.F. Intraperitoneal interferon-alpha-2b for patients with no macroscopic disease following second-look laparotomy, 324

Rawlings, G. *see* Thomas, G.M.
Reale, F.R. *see* Rose, P.G.
Rebello, G. *see* Al-Nafussi, A.I.
Redman, C.W.E. *see* Fayers, P.M.
Reynolds, R.K. *see* Helm, C.W.
Rizel, S. *see* Menczer, J.
Roberts, J. *see* Helm, C.W.
Roberts, W.S. *see* Barton, D.P.J.
Roberts, W.S. *see* Finan, M.A.
Rose, P.G., Reale, F.R., Beurskens, M.L. & Hunter, R.E. Preoperative CA-125 levels predict poor prognostic pathologic features in early stage, FIGO grade 1 and 2 endometrial adenocarcinoma, 259
Roulston, J.E. *see* Fayers, P.M.
Rustin, G. *see* Fayers, P.M.
Rustin, G.J.S. *see* O'Reilley, S.M.

Saito, T. *see* Kamura, T.
Saito, T. *see* Karu, T.
Sasano, Hironobu *see* Ito, Kiyoshi
Sato, Shinji *see* Ito, Kiyoshi
Scambia, G., Benedetti Panici, P., Ferrandini, G., Battaglia, F., Baoicchi, G., Di Stefano, P., Tinari, N., Coronetta, F., Piantelli, M., Natali, P., Iacobelli, S. & Mancuso, S. Expression of HER-2/neu oncoprotein, DNA-ploidy and

S-phase fraction in advanced ovarian cancer, 271
Scott, I.V. *see* Fayers, P.M.
Sen, D.K. *see* Sivanesarathnam, V.
Shafi, M. *see* Finn, C.B.
Shafi, M.I., Dunn, J.A., Finn, C.B., Kehoe, S., Buxton, E.J., Jordan, J.A. & Luesley, D.M. Characterization of high- and low-grade cervical intraepithelial neoplasia, 203
Shimmoto, T. *see* Karu, T.
Shingleton, H.M. *see* Helm, C.W.
Shun, F.W.W. *see* Fu, W.Y.
Sivanesarathnam, V., Sen, D.K., Jayalakshmi, P. & Ong, G. Radical hysterectomy and pelvic lymphadenectomy for early invasive cancer of the cervix—14 year experience, 231
Sivridis, E., Buckley, C.H. & Fox, H. Type I and type II estrogen and progesterone binding sites in endometrial carcinomas: their value in predicting survival, 80
Slevin, M.L. *see* Fayers, P.M.
Soong, S.-J. *see* Potter, M.E.
Soong, S.-J. *see* Helm, C.W.
Soutter, W.P. *see* Kesic, V.I.
Spencer, S. *see* Potter, M.E.
Stenwig, A.E. *see* Nordai, R.N.
Stern, P.L. *see* Connor, M.E.
Stroyer, L. *see* Bertelsen, K.
Sugihara, K. *see* Karu, T.
Sulovic, V. *see* Kesic, V.I.

Takahashi, K. *see* Imai, A.
Tamada, T. *see* Fujita, M.
Tamaya, T. *see* Imai, A.
Tani, T. *see* Fujita, M.
Tanizawa, O. *see* Fujita, M.
Thomas, G.M., Dembo, A.J., Myhr, T., Black, B., Pringle, J.F. & Rawlings, G. Long-term results of concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after surgery, 193
Thompson, S. *see* Longfield, 193
Tinari, N. *see* Scambia, G.
To, N. *see* Kamura, T.
To, N. *see* Karu, T.
Tropé, C. *see* Kamura, T.
Tropé, C.C. *see* Nordal, R.N.
Tropé, C.G. *see* Kaern, J.
Tropé, C.G. *see* Makar, A. Ph.
Tsukamoto, N. *see* Karu, T.
Tsukamoto, N. *see* Kamura, T.
Tsuruchi, N. *see* Kamura, T.
Tsuruchi, N. *see* Karu, T.
Turner, G.A. *see* Longfield, J.C.
Twiggs, L.B. *see* Carter, J.R.

Uchiyama, M. *see* Hachisuga, T.

Vergote, I. *see* Makar, A. Ph.
Vermorken, J.B. The role of chemotherapy in squamous cell carcinoma of the uterine cervix: a review, 129

Walsh, D.J. *see* Nwabineli, N.J.
Watanabe, Keiko *see* Ito, Kiyoshi
Wells, M. *see* Patel, K.R.
Wesling, F. *see* Baekelandt, M.
West, C.M.L. *see* Connor, M.E.
Wharton, J.T. *see* Patton, T.J.k
Wilkinson, N. *see* Guo, Li-Na
Wilkinson, P. *see* Fayers, P.M.
Williams, A.R.W. *see* Al-Nafussi, A.I.
Wood, R. *see* Fayers, P.M.

Yajima, Akira *see* Ito, Kiyoshi
Yancey, C. *see* Patton, T.J.
Yeung, Y. *see* Bridges, J.E.

Keyword Index

abnormal cytology in pregnancy, 239
actinomycin, 265
adenocarcinoma, 80, 245
adenosquamous, 245
advanced, 369
advanced carcinoma, 57
advanced ovarian cancer, 285
advanced ovarian carcinoma, 44
age, 147
allele loss, 293
anti-proliferative activity, 36
antibiotic prophylaxis, 94
antitumor effect, 311

binding sites, 80
borderline tumors, 299, 349

c-erbB-2 oncogene, 116
CA, 125, 116, 125, 285, 299
camptothecin analog, 36
cancer, 18, 395
carcinogens, 159
carcinoma, 199, 245
carcinoma of the cervix, 337
carcinosarcoma, 1
catheter, 208
cell cycle, 36
cervical cancer, 12, 129, 159, 169, 175, 183
cervical carcinoma, 103, 143
cervical intra-epithelial glandular neoplasia, 164
cervical intraepithelial neoplasia, 164, 253
cervicography, 395
cervix, 57, 89, 164, 245, 395
cervix dysplasia, 385
cervix neoplasms, 385
characterization, 203
chemotherapy, 110, 129, 189, 329
choriocarcinoma, 186
chronic neutropenia, 405
CIN, 89, 203
cisplatin-induced neurotoxicity, 44
colony-forming efficiency, 103
color Doppler, 279
colposcopy, 385
concomitant chemotherapy, 304
concurrent 5-FU, 193
conservative operation, 329
corpus uteri, 1
cytochrome P450, 159
cytology, 89, 395
cytoreduction, 199

diagnosis, 65
DNA ploidy, 349

early invasive cervical carcinoma, 231
early ovarian cancer, 211
electrophoresis, 253
electrosurgery, 385
endometrial carcinoma, 147, 259, 373
endometrial carcinoma cell line, 36
endometrial tumor, 122
endometrium, 80, 363
epithelial ovarian cancer, 72, 226
estrogen receptor, 80
extraperitoneal metastases, 359

fallopian tube carcinoma, 65
fecal continence, 318
flow cytometry, 265, 349
follow-up, 164

GCSF, 405
gestational trophoblastic tumors, 265
gonadotropin-releasing hormone, 311
grade, 72, 203
gynecologic malignancies, 279
gynecologic malignancy, 143

HER-2/neu, 271
high risk, 226
high-dose cisplatin, 44
histology, 12, 89
HPV, 103
human chorionic gonadotrophin, 186, 265
hyperplasia, 363
hysterectomy, 208

immunohistochemistry, 122, 159
infection, 208
interferon gamma (IFN-*), 36
interstitial radiation, 304
intraperitoneal chemotherapy, 359
intraperitoneal interferon, 324

laser conization, 183
lesion size, 203
lipid-associated sialic acid, 143
local control, 399
local flaps, 318
long-term outcome, 329
loss of heterozygosity, 293
lymph node involvement, 12

macrophage, 103
mathematical model, 265
methotrexate, 265
MHC, 103
microinvasion, 183
mitomycin, 193
mixed Mullerian tumors, 1

natural history, 373
negative second-look laparotomy, 359

ovarian, 189
ovarian cancer, 311, 324, 359
ovarian cancer prognosis, 271
ovarian carcinoma, 24, 54, 143, 293
ovarian endodermal sinus tumor, 329
ovary, 199, 349

p53 expression, 363
PCNA in ovarian neoplasms, 391
PCNA (proliferating cell nuclear antigen), 122, 154
pelvic recurrence, 304
perianal lesions, 318
phosphoinositide, 311
pregnancy, 57
preoperative CA-125, 259
progesterone receptor, 80
prognosis, 24, 54, 80, 245, 285
prognostic classifications, 24
prognostic factor, 219
prognostic factors, 211, 265, 349

radiation, 193
radiation therapy, 399
radical, 208
radical hysterectomy, 94, 231
radiosensitivity, 103
radiotherapy, 175, 337
receptor (human), 311
recurrent carcinoma of cervix, 193
reproducibility, 72

screening, 395
secretory component, 253
Sertoli-Leydig tumor, 189
small bowel, 175
smoking, 159
squamous cell, 129
squamous neoplasia, 154
stage I, 226
stage IIb cervical cancer, 219
staging, 65
suprapubic, 208
surgery, 18
surgical site-related infections, 94
surgical staging, 169
survival, 245

topoisomerase I activity, 36
transvaginal sonography, 279
treatment, 18, 65
treatment response, 265
triple incision, 18
tubal malignancies, 116

tumor marker assay, 186
type, 72

ultraradical surgery, 369
urethral, 208
uterine cervix, 154
uterine corpus carcinoma, 143
uterine/sarcoma, 110

vaginal cancer, 399
viral wart, 154
vulva, 18
vulval cancer, 405
vulvar cancer, 369

Western blotting, 253

young women, 147